Phelix Therapeutics

company

About

Dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases.

  • 11 - 50

Details

Last Funding Type
Grant
Last Funding Money Raised
$201.66K
Industries
Health Care,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
11 - 50
Operating Status
Active

Phelix Therapeutics, LLC is dedicated to saving the lives of people diagnosed with Idiopathic Pulmonary Fibrosis, and other Fibrotic Diseases, by developing innovative treatments for these fatal conditions.
Phelix Therapeutics continues to advance and commercialize the Calpain Inhibitor research and development work of Dr. Doron Greenbaum. The unique biological approach of Phelix Therapeutics relies on the insight that the connected processes of cellular injury/death and fibrosis can both be treated by inhibition of a single therapeutic target.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$201.66K
Phelix Therapeutics has raised a total of $201.66K in funding over 2 rounds. Their latest funding was raised on Jan 31, 2018 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 31, 2018 Grant $201.66K 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Phelix Therapeutics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant